Search results for "Agoni"

showing 10 items of 2493 documents

Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima–media thickness in female patients with active rheumatoid ar…

2009

The objective of the study is to evaluate the effect of TNF inhibition on carotid thickness over a 2-year period. 144 women with RA diagnosed according to ACR criteria, without clinical evidence of cardiac and/or vascular disease were enrolled and compared with 78 matched controls. All patients received methotrexate (15–20 mg weekly) for 3 months. Responders (n = 79) continued to be treated with methotrexate, non-responders (n = 40) moved to methotrexate plus a TNF alpha antagonist. Echosonographic studies of carotids were obtained before and after 2-year follow-up. A significant decrease of ca-IMT was observed in anti-TNF-treated patients (P < 0.001); on the other hand, no significant vari…

AdultCarotid Artery Diseasesmedicine.medical_specialtyImmunologyTNFGastroenterologyArthritis RheumatoidRheumatologyInternal medicineRheumatoid arthritis TNF DMARDs AtherosclerosisFemale patientmedicineHumansImmunology and AllergyRheumatoid arthritiUltrasonographyTumor Necrosis Factor-alphaVascular diseasebusiness.industryAntagonistMiddle AgedAtherosclerosismedicine.diseaseRheumatologySurgerySettore MED/16 - ReumatologiaDMARDMethotrexateTreatment OutcomeIntima-media thicknessAntirheumatic AgentsRheumatoid arthritiscardiovascular systemDrug Therapy CombinationFemaleMethotrexateTumor necrosis factor alphaTunica IntimaTunica Mediabusinessmedicine.drugRheumatology International
researchProduct

15(S)-HETE modulates LTB(4) production and neutrophil chemotaxis in chronic bronchitis.

2000

We evaluated the levels of 15(S)-hydroxyeicosatetraenoic acid [15(S)-HETE] and the expression of 15-lipoxygenase (15-LO) mRNA in induced sputum obtained from 10 control and 15 chronic bronchitis subjects. 15(S)-HETE was evaluated by reverse phase high-performance liquid chromatography separation followed by specific RIA. 15-LO mRNA expression was determined by primed in situ labeling. The levels of both soluble and cell-associated 15(S)-HETE resulted significantly higher in chronic bronchitis than in control subjects. The percentage of cells expressing 15-LO mRNA was significantly higher in chronic bronchitis than in control subjects ( P &lt; 0.01). Double staining for specific cell type ma…

AdultChronic bronchitisPhysiologyLeukotriene B4Cell SurvivalNeutrophilsNeutrophileCell CountLeukotriene B4chemistry.chemical_compoundHydroxyeicosatetraenoic AcidsMedicineArachidonate 15-LipoxygenaseHumansLung Diseases ObstructiveRNA MessengerBronchitisCells CulturedIn Situ HybridizationAgedbiologyIonophoresbusiness.industryMacrophagesSputumChemotaxisCell BiologyMiddle Agedmedicine.diseaseImmunohistochemistryChemotaxis Leukocytemedicine.anatomical_structureEicosanoidchemistryArachidonate 5-lipoxygenaseImmunologyChronic Diseasebiology.proteinBronchitisLeukotriene AntagonistsbusinessRespiratory tractAmerican journal of physiology. Cell physiology
researchProduct

The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal se…

2004

Migraine is associated with a significant productivity loss to employers, who may benefit from making a migraine intervention available to their employees.To evaluate changes in migraine-related productivity and non-workplace impairment associated with a migraine intervention program from the employer perspective.This was a pre-test post-test study of Spanish Postal Service employees with migraine. The intervention consisted of counseling from occupational health physicians and rizatriptan 10 mg for symptomatic treatment of two subsequent migraine headaches. Physicians also prescribed additional medications for migraine prophylaxis, treatment of tension headaches, and rescue medications. Mi…

AdultCounselingMalemedicine.medical_specialtyMigraine DisordersMEDLINEOccupational Health ServicesEfficiencyOccupational safety and healthIntervention (counseling)AbsenteeismmedicineHumansPostal ServicePsychiatryProductivitybusiness.industryGeneral MedicineTriazolesmedicine.diseaseRizatriptanTryptaminesSerotonin Receptor AgonistsMigraineSpainAbsenteeismCosts and Cost AnalysisFemaleHeadachesmedicine.symptombusinessmedicine.drugFollow-Up StudiesCurrent medical research and opinion
researchProduct

Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cet…

2001

Background The cause and pathogenesis of chronic urticaria are still poorly understood. IgE-independent reactions, are common in adult patients with chronic urticaria, who have daily spontaneous occurrence of weals. H1-receptor antagonists (antihistamines) are the major class of therapeutic agents used in the management of urticaria and angioedema. Nevertheless, chronic urticaria is often difficult to treat and may not be controlled by antihistamines alone. It has been postulated that mediators other than histamine, such as kinins, prostaglandin and leukotrienes, may be responsible for some of the symptoms in urticaria which are not controlled by antihistamines. In this study, which was ran…

AdultCyclopropanesMalemedicine.medical_specialtyAdolescentUrticariaImmunologyAcetatesSulfidesPlaceboGastroenterologyDouble-Blind Methodimmune system diseasesInternal medicinemedicineImmunology and AllergyHumansskin and connective tissue diseasesAdverse effectMontelukastAgedLeukotrieneAngioedemaAspirinLeukotriene receptorbusiness.industryIncidenceMiddle Agedmedicine.diseaseCetirizineCetirizineFood intoleranceTreatment OutcomeItalyImmunologyChronic DiseaseHistamine H1 AntagonistsQuinolinesLeukotriene AntagonistsFemaleFood AdditivesSleep Stagesmedicine.symptombusinessFood Hypersensitivitymedicine.drugClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for…

2004

BACKGROUND: H 1 -receptor antagonists are considered to be particularly effective in reducing pruritus, and they are therefore recommended as first-line treatment in patients with chronic idiopathic urticaria (CIU). Recently, antileukotriene receptors have been used in patients with CIU, either administered as monotherapy or combined with H 1 -receptor antagonists. OBJECTIVE: We compared the clinical efficacy of 5 mg of desloratadine administered once daily either as monotherapy or combined with a leukotriene antagonist, 10 mg of montelukast daily, and 10 mg of montelukast administered daily as monotherapy for the treatment of patients affected by CIU with placebo. METHODS: One hundred sixt…

AdultCyclopropanesMalemedicine.medical_specialtyHistamine H1 Antagonists Non-SedatingSettore MED/09 - Medicina InternaAdolescentUrticariamedicine.medical_treatmentImmunologyPlacebo-controlled studyRandomized placebo-controlled trial; desloratadine; montelukast; chronic idiopathic urticariaAcetatesSulfidesPlaceboGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineImmunology and AllergyHumansMontelukastAgedDesloratadineLeukotriene E4Leukotriene receptorbusiness.industrydesloratadineRandomized placebo-controlled trialLoratadineMiddle AgedAntileukotrieneTreatment OutcomechemistryAnesthesiachronic idiopathic urticariaChronic DiseasemontelukastQuinolinesLeukotriene AntagonistsFemalebusinessmedicine.drug
researchProduct

Activity of the antiestrogenic cajanin stilbene acid towards breast cancer

2014

Antiestrogenic therapy is a mainstay for estrogen receptor (ERα)-positive breast cancer. Due to the development of resistance to established antihormones such as tamoxifen, novel compounds are required. The low abundant cajanin stilbene acid (CSA) recently isolated by us from Pigeon Pea (Cajanus cajan) has structural similarities with estrogen. We analyzed the cytotoxic and anticancer activity of CSA in ERα-positive and -negative human breast cancer cells in vitro, in vivo and in silico. CSA exerts anticancer and antiestrogenic activities towards ERα-positive breast cancer, and it showed cytotoxicity towards tamoxifen-resistant MCF-7 cells, implying that CSA may be active against tamoxifen-…

AdultEndocrinology Diabetes and MetabolismClinical BiochemistryMice NudeEstrogen receptorBreast NeoplasmsPharmacologyBiochemistryBreast cancerCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsStilbenesAnimalsHumansMedicineCytotoxic T cellPromoter Regions Geneticskin and connective tissue diseasesCytotoxicityMolecular BiologyNutrition and Dieteticsbusiness.industryEstrogen AntagonistsEstrogen Receptor alphaCancerMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysSalicylatesGene Expression Regulation NeoplasticTamoxifenReceptors EstrogenCancer cellMCF-7 CellsFemalebusinessEstrogen receptor alphaTamoxifenmedicine.drugThe Journal of Nutritional Biochemistry
researchProduct

A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy

2007

Mutations in the Angiogenin gene (ANG) linked to 14q11.2 have been recently discovered to be associated with Amyotrophic Lateral Sclerosis (ALS) in Irish and Scottish populations. In our study we investigated the role of ANG gene in ALS patients from southern Italy. We found a novel mutation in the signal peptide of the ANG gene in a sporadic patient with ALS (SALS). The molecular analysis of the ANG gene also demonstrated an allelic association with the rs11701 single nucleotide polymorphism (SNP) in familial ALS (FALS) but not in SALS patients. Our finding supports the evidence that the ANG gene is involved in ALS.

AdultGenetic MarkersMaleSignal peptideAngiogenin geneAngiogeninGenetic LinkageDNA Mutational AnalysisSingle-nucleotide polymorphismGene mutationBiologyPolymorphism Single NucleotidemedicineHumansSNPGenetic Predisposition to DiseaseGenetic TestingAlleleAmyotrophic lateral sclerosisGeneGenetics (clinical)AgedChromosomes Human Pair 14Motor NeuronsGeneticsAmyotrophic Lateral SclerosisChromosome MappingRibonuclease PancreaticMiddle Agedmedicine.diseaseAssociation studyAmino Acid SubstitutionItalyNeurologyCytoprotectionMutationNerve DegenerationPediatrics Perinatology and Child Healthcardiovascular systemCancer researchFemaleNeurology (clinical)ALShormones hormone substitutes and hormone antagonistsNeuromuscular Disorders
researchProduct

Pituitary-adrenal responses to corticotropin-releasing factor in late onset 21-hydroxylase deficiency

1990

Intravenous corticotropin-releasing factor (CRF) and adrenocorticotropin hormone (ACTH) were administered in patients with adult onset 21-hydroxylase deficiency to compare their diagnostic capability as well as to investigate hypothalamic-pituitary-adrenal function in this disorder. Responses of 17-hydroxyprogesterone, which were markedly elevated compared with controls, were identical with CRF and ACTH. However, intravenous ACTH resulted in higher androstenedione levels in comparison to CRF. Adrenocorticotropin hormone also resulted in decreased cortisol responses, confirming a defect in steroidogenesis, a finding that was not evident with CRF. Plasma ACTH responses to CRF were similar in …

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentCorticotropin-Releasing HormoneLate onsetPeptide hormoneDecreased cortisolAdrenocorticotropic HormoneInternal medicineAdrenal GlandsHydroxyprogesteronesmedicineHumansTestosteroneIn patientAndrostenedioneAdrenal Hyperplasia Congenitalbiologybusiness.industry17-alpha-HydroxyprogesteroneAndrostenedione21-HydroxylaseObstetrics and GynecologyDiagnostic testEndocrinologyReproductive MedicinePituitary GlandSteroid Hydroxylasesbiology.proteinFemalebusinesshormones hormone substitutes and hormone antagonistsHormoneFertility and Sterility
researchProduct

Ovine corticotropin-releasing factor and dexamethasone responses in hyperandrogenic women

1990

Eighteen hyperandrogenic, hirsute women received ovine corticotropin-releasing factor (CRF; 1 microgram/kg) as well as a dexamethasone (DEX) suppression test. Nine of the 18 hirsute women exhibited increased DEX sensitivity. Plasma adrenocorticotropic hormone (ACTH) responses after ovine CRF were significantly lower in the DEX-sensitive subgroup, but serum androstenedione was higher. Baseline serum androgen levels could not predict DEX responses. A significant negative correlation existed between the suppression of androgens after DEX and the increase in ACTH after ovine CRF. The suppression of androgen correlated with the ratio of the increase in androgen to the increase in ACTH after ovin…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentCorticotropin-Releasing Hormonemedicine.drug_classMicrogramAdrenocorticotropic hormoneDexamethasoneAdrenocorticotropic HormoneInternal medicinepolycyclic compoundsAnimalsHumansMedicineAndrostenedioneDexamethasonehirsutismSheepbusiness.industryHyperandrogenismObstetrics and GynecologyAndrogen AntagonistsAndrogenmedicine.diseasePathophysiologyEndocrinologyReproductive MedicineAndrogensFemalebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugFertility and Sterility
researchProduct

Physiological Estrogen Replacement May Enhance the Effectiveness of the Gonadotropin-Releasing Hormone Agonist in the Treatment of Hirsutism

1994

GnRH agonists (GnRH-A) have been used for the treatment of hirsutism in women with ovarian hyperandrogenism. However, significant side-effects, including vasomotor symptoms and bone loss, have prevented the long term use of this therapy. In this study, we evaluated the effects of low dose (physiological) estrogen replacement on the side-effects and clinical and hormonal parameters of 22 hirsute women with ovarian hyperandrogenism when treated with a long-acting GnRH-A, Decapeptyl. Ten patients with Ferriman-Gallwey (FG) scores averaging 13.4 +/- 1.5 were randomly assigned to be treated with Decapeptyl alone (3.75 mg, im, every 28 days for 6 months), and 12 other patients with FG scores aver…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryOvaryMedroxyprogesterone AcetateGonadotropin-releasing hormoneBiochemistryGonadotropin-Releasing HormoneEndocrinologyGonadotropin-releasing hormone agonistInternal medicinemedicineHumansMedroxyprogesterone acetateEstrogen replacementConjugated Equine EstrogensTestosteronehirsutismTriptorelin PamoateVasomotorbusiness.industryEstrogen Replacement TherapyBiochemistry (medical)HyperandrogenismObstetrics and GynecologyDrug SynergismGeneral Medicinemedicine.diseaseMenstruationmedicine.anatomical_structureEndocrinologyEstrogenGonadotropins PituitaryAndrogensDrug Therapy CombinationFemalebusinesshormones hormone substitutes and hormone antagonistsHormonemedicine.drugObstetrical &amp; Gynecological Survey
researchProduct